Man Group plc Acquires Shares of 935,186 Edwards Lifesciences Corporation $EW

Man Group plc acquired a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, Holdings Channel reports. The firm acquired 935,186 shares of the medical research company’s stock, valued at approximately $84,597,000.

Other institutional investors also recently made changes to their positions in the company. Rehmann Capital Advisory Group boosted its stake in shares of Edwards Lifesciences by 2.1% during the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock valued at $546,000 after buying an additional 130 shares during the last quarter. McIlrath & Eck LLC increased its stake in shares of Edwards Lifesciences by 14.6% in the fourth quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock worth $90,000 after buying an additional 135 shares during the last quarter. Quadrant Capital Group LLC raised its holdings in Edwards Lifesciences by 0.9% in the fourth quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock valued at $1,288,000 after acquiring an additional 136 shares in the last quarter. Stephens Inc. AR raised its holdings in Edwards Lifesciences by 5.4% in the fourth quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company’s stock valued at $239,000 after acquiring an additional 144 shares in the last quarter. Finally, Composition Wealth LLC boosted its stake in Edwards Lifesciences by 1.6% during the 4th quarter. Composition Wealth LLC now owns 9,331 shares of the medical research company’s stock valued at $795,000 after acquiring an additional 147 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have weighed in on EW. BTIG Research raised their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Leerink Partners raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $87.00 to $101.00 in a research report on Friday, July 24th. JPMorgan Chase & Co. lifted their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Friday, July 24th. Finally, UBS Group started coverage on Edwards Lifesciences in a report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price objective for the company. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Trading Up 0.5%

NYSE:EW opened at $90.92 on Wednesday. The firm has a market capitalization of $52.35 billion, a P/E ratio of 52.25, a P/E/G ratio of 2.37 and a beta of 0.85. The business has a 50 day simple moving average of $89.35 and a 200 day simple moving average of $84.82. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period last year, the company earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Activity

In related news, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 2,425 shares of company stock valued at $219,199 in the last 90 days. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.